AYTU BIOPHARMA INC

For the period ended Mar 31, 2024. Filed May 15, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 15, 2024

AYTU$1.81+1.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Consolidated Statements of Operations

(in thousands, except per share data)

Three Months Ended · Nine Months Ended
	March 31,		March 31,
	2024	2023	2024	2023
Net revenue	$17,993	$22,733	$63,026	$76,667
Cost of sales	6,300	9,990	20,346	28,599
Gross profit	11,693	12,743	42,680	48,068
Operating expenses:
Selling and marketing	6,549	12,804	20,547	33,466
General and administrative	5,442	7,177	17,837	22,517
Research and development	619	856	1,747	3,630
Amortization of intangible assets	1,303	1,198	3,909	3,593
Restructuring costs	244	—	244	—
Impairment expense	—	—	—	2,600
Gain from contingent consideration	—	(734)	—	(504)
Total operating expenses	14,157	21,301	44,284	65,302
Loss from operations	(2,464)	(8,558)	(1,604)	(17,234)
Other expense, net	(1,195)	(1,215)	(3,083)	(3,527)
Gain (loss) on derivative warrant liabilities	1,017	2,573	(5,467)	6,167
Loss before income tax	(2,642)	(7,200)	(10,154)	(14,594)
Income tax expense	(245)	—	(1,073)	—
Net loss	$(2,887)	$(7,200)	$(11,227)	$(14,594)
Basic and diluted weighted-average common shares outstanding	5,533,555	3,726,779	5,511,089	3,099,130
Basic and diluted net loss per common share	$(0.52)	$(1.93)	$(2.04)	$(4.71)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.